Added to YB: 2026-04-22
Pitch date: 2026-04-20
ETON [neutral]
Eton Pharmaceuticals, Inc.
-6.25%
current return
Author Info
No bio for this author
Company Info
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Market Cap
$683.2M
Pitch Price
$25.11
Price Target
39.33 (+56%)
Dividend
N/A
EV/EBITDA
76.76
P/E
-146.44
EV/Sales
8.61
Sector
Pharmaceuticals
Category
growth
Monthly Core Conviction #1: ETON and The Full M&A Book
ETON (update): Rare pediatric/orphan disease consolidator scaling to $500M rev by 2030. 2026 rev guide $110M (+40% YoY), exit-2027 target $200M. Adj EBITDA margin 30%+ in 2026, rising to 50% by 2028. Recent launches DESMODA/HEMANGEOL ramping. Analyst avg PT $39.33 (+57% upside). Risks: execution, regulatory timelines, tight cash.
Read full article (2 min)